Abstracts Archive - Page 570 of 2607 - ACR Meeting Abstracts

Abstract Number: 1303 • ACR Convergence 2022
Planning Transition in Times of Transition: Is There a Virtual Pathway from Pediatric to Adult Care?
Ben Danna, Monique Maher, Miriah Gillispie-Taylor and Tiphanie Vogel, Baylor College of Medicine, Houston, TX
Background/Purpose: The BRIDGE (Baylor Rheumatology Initiative: Developing and Guiding Engagement) program is a quality improvement initiative to develop a safe, comprehensive pathway for our patients…
Abstract Number: 1297 • ACR Convergence 2022
A Paediatric-Adult Provider Dyad Care Model Improves Transition from Paediatric to Adult Health Care for Youth with Childhood-Onset Systemic Lupus Erythematosus
Tala El Tal¹, Abdulaziz el Mutairi¹, Amanda Steiman² and Earl Silverman³, ¹The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ²Sinai Health System, Toronto, ON, Canada, ³The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multi-system autoimmune disease affecting 1 in 1000 individuals, of whom 20% develop the disease in childhood. Childhood-onset…
Abstract Number: 1309 • ACR Convergence 2022
Evaluation of Preference and Efficacy in the Treatment of Glucocorticoid-induced Osteoporosis in Patients with Autoimmune Diseases Receiving Zoledronic Acid
Ji-Won Kim¹, Ju-Yang Jung¹, Hyoun-Ah Kim¹ and Chang-Hee Suh², ¹Ajou University School of Medicine, Suwon, Republic of Korea, ²Ajou University Hospital, Suwon, Republic of Korea
Background/Purpose: The most commonly used drugs for glucocorticoid-induced osteoporosis (GIOP) is bisphosphonates, which include oral alendronate and risedronate, and intravenous zoledronic acid. Among them, zoledronic…
Abstract Number: 1310 • ACR Convergence 2022
Is the Trabecular Bone Score (TBS) a Useful Tool in Patients with Diffuse Idiopathic Skeletal Hyperostosis (DISH)?
Bjoern Buehring¹, David Kiefer², Celina Mueller², Roshnak Parvaee², Marianti Ifanti², Ioana Andreica³, Timm Westhoff⁴, Rainer Wirth⁴, Xenofon Baraliakos⁵, Nina Babel⁴ and Juergen Braun², ¹Bergisches Rheuma-Zentrum, Wuppertal, Germany, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ⁴Marienhospital Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Patients with rheumatic and musculoskeletal diseases (RMD) have an increased fracture risk (FxR). Diffuse idiopathic skeletal hyperostosis (DISH) is a non-inflammatory disease characterized by…
Abstract Number: 1300 • ACR Convergence 2022
Impact of Demographics and Health Literacy on Transition Readiness for Adolescents with Rheumatic Disease
Maryem Al Manaa¹, Chan-hee Jo², Una Makris³, Nicole Bitencourt⁴, Tracey Wright⁵ and Lorien Nassi⁶, ¹UT Southwestern, Dallas, TX, ²Scottish Rite Hospital for Children, Dallas, TX, ³UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁴Loma Linda University Health, San Bernardino, CA, ⁵UT Southwestern, Plano, TX, ⁶University of Texas Southwestern, Dallas, TX
Background/Purpose: The transition to adult care for adolescents with rheumatic disease is a vulnerable period for many and can be associated with adverse outcomes. Adolescents…
Abstract Number: 1308 • ACR Convergence 2022
Prevalence and Therapeutic Practices of Osteoporosis in Sarcoidosis in the United States: A Nationwide Registry Study
Diala Alawneh¹, Moustafa Younis², Romesa Hassan¹, Bashar Alzghoul², Shiva Arami¹, Tricha Shivas³, Mary McGowan³, Khaldoon Alawneh⁴, Christian Ascoli¹ and Nadera Sweiss¹, ¹University of Illinois at Chicago, Chicago, IL, ²University of Florida, Gainesville, FL, ³Foundation for Sarcoidosis Research, Chicago, IL, ⁴Jordan University of Science and Technology, Irbid, Jordan
Background/Purpose: Patients with sarcoidosis are at an increased risk of developing osteoporosis due to the active inflammatory state and chronic corticosteroid use. Proper dosing of…
Abstract Number: 1322 • ACR Convergence 2022
Follow up of Incidentally Noted Vertebral Compression Fractures
Jason Yang¹, Alexia Hwang¹, Megan Brochu², Krista Sabina², Meridith Malysz², Bruce Weinstein³ and Jonathan Cheah¹, ¹UMass Chan Medical School, Worcester, MA, ²UMass Memorial Health, Worcester, MA, ³UMass Memorial Health, UMass Chan Medical School, Worcester, MA
Background/Purpose: Vertebral compression fractures (VCFs) in general represent a clinical diagnosis of osteoporosis, predisposing to an increased risk of additional fractures. However, a significant number…
Abstract Number: 1316 • ACR Convergence 2022
A Cluster of Paget Disease of the Bone in Black or African American Patients in a Veteran Population
Mariana Urquiaga and Angelo Gaffo, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Genetic and environmental factors have been implicated in the pathogenesis of Paget Disease of the Bone (PDB). Although the disease is described more frequently…
Abstract Number: 1318 • ACR Convergence 2022
Low-Dose Prednisolone (≤5 Mg/d) Is Not Associated with Deleterious Effects on Bone Mineral Density: Baseline Findings in a Cohort of Rheumatic Disease Patients with Prior Glucocorticoid Exposure
Edgar Wiebe¹, Dörte Huscher², Desirée Schaumburg¹, Andriko Palmowski¹, Sandra Hermann¹, Thomas Buttgereit³, Robert Biesen⁴, Gerd Burmester⁵, Yannick Palmowski⁶, Maarten Boers⁷, John Stone⁸, Christian Dejaco⁹ and Frank Buttgereit¹⁰, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Institute of Biometry and Clinical Epidemiology, and Berlin Institute of Health, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ³Department of Dermatology, Venerology and Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵Charité University Medicine Berlin, Berlin, Germany, ⁶Spine Department, Center for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁷Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁸Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁹Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, and Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ¹⁰Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany
Background/Purpose: Inflammatory rheumatic and musculoskeletal diseases (iRMD) are associated with increased systemic bone loss that is mediated by chronic inflammation, treatment with glucocorticoids (GC), and…
Abstract Number: 1314 • ACR Convergence 2022
Response Rates for Lumbar Spine, Total Hip, and Femoral Neck Bone Mineral Density with Abaloparatide in Men: Results from the ATOM Study
Ruban Dhaliwal¹, David Kendler², Kenneth Saag³, Steven Ing⁴, Andrea Singer⁵, Robert Adler⁶, Leny Pearman⁷, Yamei Wang⁷ and Bruce Mitlak⁸, ¹SUNY Upstate Medical University, Syracuse, NY, ²University of British Columbia, Vancouver, BC, Canada, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Ohio State University Wexner Medical Center, Colombus, OH, ⁵MedStar Georgetown University Hospital, Washington, DC, ⁶Hunter Holmes McGuire Veterans Affairs Medical Center-Richmond, Richmond, VA, ⁷Radius Health, Inc., Waltham, MA, ⁸Radius Health, Inc, Boston, MA
Background/Purpose: In the Abaloparatide for the Treatment of Men with Osteoporosis (ATOM) study, 12 months of abaloparatide therapy resulted in rapid and significant improvements in…
Abstract Number: 1325 • ACR Convergence 2022
The Risks of Osteoporotic Fracture After Lung Transplant: A Retrospective Cohort Study at an International Transplant Center
Adil Vural¹, Sarah Keller², Neel Tapryal³, Komal Mushtaq⁴, Hassan Shaheen¹, Chao Zhang², Marie Budev², Abby Abelson² and Chad Deal⁵, ¹Cleveland Clinic, Westlake, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic, Rocky River, OH, ⁴Cleveland Clinic, Fairview Park, OH, ⁵Cleveland Clinic, Shaker Heights, OH
Background/Purpose: Osteoporotic fractures are a well-known complication of lung transplant (LT) and can significantly impact the quality of life of LT recipients. Although much is…
Abstract Number: 1324 • ACR Convergence 2022
Treatment Patterns in Women with Post-Menopausal Osteoporosis Using Abaloparatide: A Real-world Observational Study
Deborah Gold¹, Tammy Beckett², Chad Deal³, Andrew L James⁴, Jacqueline M Kernaghan⁵, Mahshid Mohseni⁶, Abigail McMillan⁷, Tom Bailey⁷, Leny Pearman⁸, John Caminis⁸, Yamei Wang⁸ and Setareh A Williams⁹, ¹Duke University Medical Center, Durham, NC, ²Department of Orthopaedics, Orthopaedic Associates of Grand Rapids Research and Education Institute, Grand Rapids, MI, ³Cleveland Clinic, Shaker Heights, OH, ⁴Columbia Orthopaedic Groups LLP, Columbia, MO, ⁵Prospect Health Access Network, Springfield, PA, ⁶Washington University School of Medicine, St. Louis, MO, ⁷Observational Research Adelphi Real World, Macclesfield, United Kingdom, ⁸Radius Health, Inc., Waltham, MA, ⁹CobbsCreek Healthcare, Newtown Square, PA
Background/Purpose: Abaloparatide (ABL) is approved for treatment of women with postmenopausal osteoporosis (PMO) at high risk for fracture. The study evaluated real-world treatment patterns for…
Abstract Number: 1326 • ACR Convergence 2022
Impact of COVID-19 Severity on Bone Mineral Density, Sarcopenia and Physical Performance Among Older Adults Following Hospitalization: A Pilot Study
Diego Cabrera¹, Clara Wong², Andrew Cohen³, Lauren Ferrante³, Alexandra Hajduk³ and Evelyn Hsieh¹, ¹Section of Rheumatology, Allergy and Immunology, Yale School of Medicine, New Haven, CT, ²Yale School of Public Health, New Haven, CT, ³Yale School of Medicine, New Haven, CT
Background/Purpose: Altered bone mineral density (BMD), muscle mass and physical performance has been associated with adverse outcomes, however, the effect of COVID-19 on the musculoskeletal…
Abstract Number: 1267 • ACR Convergence 2022
Accuracy of Financial Disclosures in American-Based Rheumatology Journals
Mary Guan¹, Michael Pillinger² and Aryeh Abeles³, ¹New York University Grossman School of Medicine, Brooklyn, NY, ²NYU Grossman School of Medicine, New York, NY, ³New York University Grossman School of Medicine, Wallingford, CT
Background/Purpose: Prior studies demonstrated that authors of publications may not accurately disclose their financial relationships with industry. One recent study reported that among authors of…
Abstract Number: 1216 • ACR Convergence 2022
Subclinical Vascular Disease Is More Prevalent in above-30 Adult Fibromyalgia: A Preliminary Report of a Hospital-based Cross-sectional Study from South India
Salil Ganu, C. B. Mithun and Jyothi Visalakshy, Amrita Institute of Medical Sciences, Kochi, India
Background/Purpose: Fibromyalgia is known to be associated with cardiovascular events and mortality. We aimed to compare the prevalence of subclinical atherosclerosis (SAT), a surrogate marker…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].